ClinicalTrials.gg
RecruitingNCT06627270Updated Nov 12, 2026

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

A Phase 2 interventional study of Metronidazole and Chlorhexidine in Oral Squamous Cell Carcinoma, Oral Cancer and Head and Neck Cancer, sponsored by Case Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Case Comprehensive Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Squamous Cell Carcinoma of Head and Neck by Case Comprehensive Cancer Center — 1 open to participants now, 1 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · Case Comprehensive Cancer Center.

Planned enrollment
3rd of 14
30 · median 14
Started
2025
with 1 other
Phase 2
6 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Squamous Cell Carcinoma of Head and Neck by Case Comprehensive Cancer Center, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 2, and was the 13th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

1 of the 14 studies in Squamous Cell Carcinoma of Head and Neck by Case Comprehensive Cancer Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Squamous Cell Carcinoma of Head and Neck by Case Comprehensive Cancer Center, or all of them as a file.
02

Study summary

The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer.

Read the detailed description

The prognosis for patients with locally advanced, non-Human Papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCC) remains poor. The immunosuppressive tumor immune microenvironment in HNSCC presents a significant barrier to both conventional and immune-based therapies. Recent studies have indicated that dysbiotic oral microbiota, particularly in the context of periodontal disease, can contribute to chronic oral mucosal inflammation and the recruitment of suppressive immune cell infiltrates. Bacterial-induced chronic inflammation may play a crucial role in treatment resistance in HNSCC. Understanding the impact of microbial modulation on the tumor immune microenvironment in HNSCC could lead to the identification of novel therapeutic targets.

In this single-arm phase II clinical trial, oral cancer patients will be treated with oral metronidazole and CHX rinses prior to surgery. Investigator will assess the ability for the treatment to reduce the absolute amount of intratumoral bacteria and evaluate changes in the intratumoral bacterial community and infiltrating immune cells.

03

Conditions studied

  • Oral Squamous Cell Carcinoma
  • Oral Cancer
  • Head and Neck Cancer
  • Head and Neck Carcinoma

Keywords

  • Metronidazole
  • Chlorhexidine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed squamous cell carcinoma of the oral cavity
  • Must have planned surgery for curative intent
  • Participants ≥ 18 years of age
  • Participants must have the ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Known allergy to metronidazole and/or chlorhexidine
  • Severe liver or kidney disease as determined by history of laboratory tests
  • Participants actively drinking alcohol (unable to abstain for the 10 day antibiotic period)
  • Recurrent oral cancer after prior radiation or chemoradiation
  • Participants with unresectable oral cancer
  • Participants unable to tolerate oral rinse or unable to have metronidazole administered by mouth or by feeding tube
  • Participants currently or have taken other antibiotics within the prior 30 days
  • Participant is pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    10 days of metronidazole and chlorhexidine

    Participants will receive metronidazole (500 mg t.i.d. x 10 days) and chlorhexidine (10 ml t.i.d. x 10 days) prior to surgical resection.

    Drug: Metronidazole · Other: Chlorhexidine

Interventions

  • Participants will receive metronidazole (500 mg t.i.d. x 10 days)

  • OtherChlorhexidine

    Mouth rinse chlorhexidine (10 ml t.i.d. x 10 days)

    Also known as: CHX

06

What researchers measure

Primary outcomes

  1. Change in absolute amount of intraumoral bacteria as quantified by 16S rRNA qPCR

    The difference between pre-treatment and post-treatment tumor bacteria burden will be assessed.

    Time frame: Baseline, surgery (10 days post intervention)

Secondary outcomes

  1. Change in absolute amount of intraumoral bacteria in post treatment participants compared to control patients as quantified by 16S rRNA qPCR

    Time frame: Baseline, surgery (10 days post intervention)

  2. Disease-free survival

    Time frame: Time from date of randomization to recurrence, second primary malignancy, or death, as determined by standard of care surveillance, up to three years.

  3. Overall Survival

    Time frame: Time from date of randomization to recurrence, second primary malignancy, or death, as determined by standard of care surveillance, up to three years.

07

Study locations

1 of 1 sites recruiting
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
    • Natalie Silver, MD · Contact
08

References and documents

Individual participant data

Plan to share: Yes — RNAseq results will be shared upon publication, not patient identifiers will be shared

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available at the time of publication or after 3 years

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 17 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Jan 2027 and completion Oct 2027 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 4, 2024
StartActual
Jul 22, 2025
Primary completionEst.
Jan 1, 2027was Oct 2026
CompletionEst.
Jan 1, 2027was Oct 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Jan 1, 2027
Nov 12, 2026
Study completion
Oct 1, 2027→Jan 1, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 1, 2026→Jan 1, 2027
    Study completion Oct 1, 2027→Jan 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06627270
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Jul 22, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Natalie Silver, MD
Contact
silvern@ccf.org
216-219-3267
Natalie Silver, MD
principal investigator · Case Comprehensive Cancer Center, Cleveland Clinic Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion